Celexa Generics Clear FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Five ANDAs for generic versions of Forest’s antidepressant approved; 180-day exclusivity was not available. Forest has been transitioning patients to the follow-on agent Lexapro.
You may also be interested in...
Forest Takes "Wait And See" Approach On Effect Of Antidepressant "Black Box" Labeling
The company does not anticipate a "dramatic disruption" to the marketplace since the safety issues have been widely publicized, COO Goodman says. He suggests that the effect on Lexapro sales could mirror the temporary dip seen when the safety issues first surfaced last summer.
Forest Takes "Wait And See" Approach On Effect Of Antidepressant "Black Box" Labeling
The company does not anticipate a "dramatic disruption" to the marketplace since the safety issues have been widely publicized, COO Goodman says. He suggests that the effect on Lexapro sales could mirror the temporary dip seen when the safety issues first surfaced last summer.
Forest Keeps Up Lexapro Detailing Pressure In Face Of Competition
Forest's antidepressant continues to be the most detailed product in the class, the company says; aggressive detailing is increasingly important with Forest's loss of exclusivity for Celexa and Lilly's launch of Cymbalta. Forest expects Lexapro to be approved for social anxiety and panic disorders early this year.